/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Abeona Therapeutics Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.66 0.0396(3.96%) ABEO at 04 Dec 2025 04:24 PM Biotechnology
Lowest Today 4.54
Highest Today 4.78
Today’s Open 4.57
Prev. Close 4.55
52 Week High 7.54
52 Week Low 3.93
Day’s Range: Low 4.54 High 4.78
52-Week Range: Low 3.93 High 7.54
1 day return -
1 Week return -6.42
1 month return +3.72
3 month return -31.07
6 month return -26.58
1 year return -21.14
3 year return +26.6
5 year return -87.45
10 year return -

Institutional Holdings

Nantahala Capital Management, LLC 8.52

Adage Capital Partners Gp LLC 5.99

BlackRock Inc 5.85

Suvretta Capital Management, LLC 5.22

Vanguard Group Inc 4.89

Western Standard LLC 4.08

Vivo Capital, LLC 3.59

Vanguard Total Stock Mkt Idx Inv 2.53

BOONE CAPITAL MANAGEMENT LLC 2.45

Geode Capital Management, LLC 2.16

iShares Russell 2000 ETF 2.08

Propel Bio Management LLC 1.90

Morgan Stanley - Brokerage Accounts 1.89

SILVERARC CAPITAL MANAGEMENT, LLC 1.79

JPMorgan Chase & Co 1.62

683 Capital Management LLC 1.46

Kennedy Capital Management Inc 1.31

State Street Corp 1.14

NAN FUNG TRINITY (HK) Ltd 1.09

Simplify Asset Management Inc. 1.09

Simplify Propel Opportunities ETF 1.09

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Citigroup Inc 1.07

Kennedy Micro Cap 1.03

Newtyn Management LLC 0.94

Fidelity Small Cap Index 0.86

iShares Russell 2000 Growth ETF 0.70

Fidelity Extended Market Index 0.52

Vanguard Russell 2000 ETF 0.41

State St Russell Sm Cap® Indx SL Cl I 0.30

Kennedy Micro Cap Opportunities 0.28

iShares Core S&P Total US Stock Mkt ETF 0.22

Schwab Small Cap Index 0.21

NT R2000 Index Fund - NL 0.21

Fidelity Total Market Index 0.19

iShares Micro-Cap ETF 0.19

Extended Equity Market Fund K 0.18

NT R2000 Index Fund - DC - NL - 3 0.16

iShares Russell 2000 Small-Cap Idx Instl 0.15

Russell 2500™ Index Fund F 0.14

Market Status

Strong Buy: 5

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 246.57 M

PB Ratio 1.5112

PE Ratio 3.9565

Enterprise Value 75.75 M

Total Assets 108.93 M

Volume 1139013

Company Financials

Annual Revenue FY23:3568000 3.6M, FY22:1414000 1.4M, FY21:3000000 3.0M, FY20:10000000 10.0M, FY19:0 0.0M

Annual Profit FY23:1863000 1.9M, FY22:964000 1.0M, FY21:3000000 3.0M, FY20:10000000 10.0M, FY19:-48566000 -48.6M

Annual Net worth FY23:-44718000 -44.7M, FY22:-31809000 -31.8M, FY21:-88606000 -88.6M, FY20:-88349000 -88.3M, FY19:-76682000 -76.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:400000 0.4M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-488000 -0.5M, Q2/2025:300000 0.3M, Q1/2025:-815000 -0.8M, Q3/2024:0 0.0M, Q2/2024:-1667000 -1.7M

Quarterly Net worth Q3/2025:-5161000 -5.2M, Q2/2025:108833000 108.8M, Q1/2025:-12029000 -12.0M, Q3/2024:-30269000 -30.3M, Q2/2024:7406000 7.4M

Fund house & investment objective

Company Information Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Organisation Biotechnology

Employees 136

Industry Biotechnology

CEO Dr. Vishwas Seshadri M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow